Lithium and triiodothyronine augmentation of antidepressants

To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone.

We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant.

All groups improved significantly over the 2 weeks of treatment, but there were no significant between-group differences.

There may be no advantage to a combination of these augmenting agents, although we failed to show separation between active treatments and placebo.